PST 611
Alternative Names: EYS-611; PST-611Latest Information Update: 28 Jan 2026
At a glance
- Originator Eyevensys
- Developer Eyevensys; PulseSight Therapeutics
- Class Antiglaucomas; Eye disorder therapies; Gene therapies; Neuroprotectants
- Mechanism of Action Gene transference
-
Orphan Drug Status
Yes - Retinitis pigmentosa
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Dry macular degeneration
- No development reported Glaucoma; Retinitis pigmentosa
Most Recent Events
- 28 Jan 2026 No recent reports of development identified for preclinical development in Glaucoma in France (Intraocular, Needle-free injection)
- 28 Jan 2026 No recent reports of development identified for preclinical development in Retinitis-pigmentosa in France (Intraocular, Needle-free injection)
- 22 Jan 2026 Pharmacodynamics data from a phase I trial in Dry macular degeneration released by PulseSight Therapeutics